Exact Sciences Earnings: Here’s Why Investors are Selling Shares Now

  Google+ | + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Exact Sciences Corporation (NASDAQ:EXAS) had a loss and missed Wall Street’s expectations, AND met the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 4.49%.

These stocks are hitting our Profit Targets. Click here now to discover winning stocks!

Exact Sciences Corporation Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased to $-0.22 in the quarter versus EPS of $-0.18 in the year-earlier quarter.

Revenue: Decreased 0% to $1.04 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Exact Sciences Corporation reported adjusted EPS loss of $0.22 per share. By that measure, the company missed the mean analyst estimate of $-0.18. It met the average revenue estimate of $1.04 million.

Quoting Management: “We continue to make good progress towards completing the FDA submission for our non-invasive, stool-DNA-based colorectal cancer screening test,” said Kevin T. Conroy, the company’s president and chief executive. “We remain confident that the clinical trial will deliver strong results, and continue to actively and systematically prepare for the test’s commercialization.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business